Feds help NewLink, Mer­ck out with some added cash for Ebo­la vac­cine

Two months af­ter NewLink was forced to re­struc­ture and slash staff in the wake of a Phase III de­ba­cle on pan­cre­at­ic can­cer, the Ames, IA-based biotech and its Big Phar­ma part­ner Mer­ck can cel­e­brate some added fed­er­al re­search and man­u­fac­tur­ing sup­port for their Ebo­la vac­cine.

BAR­DA — the Bio­med­ical Ad­vanced Re­search and De­vel­op­ment Au­thor­i­ty — is hand­ing over $25 mil­lion in cash to back up work on V920. There’s an­oth­er $51 mil­lion in added sup­port if BAR­DA choos­es to hand it over. The R&D ops group has al­ready pro­vid­ed $76.8 mil­lion for this project, which was sped up con­sid­er­ably dur­ing a re­cent out­break that has since burned out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.